PMID- 16370389
OWN - NLM
STAT- MEDLINE
DCOM- 20060619
LR  - 20051222
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 6
IP  - 12
DP  - 2005 Dec
TI  - Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic 
      approach?
PG  - 1240-5
AB  - Dendritic cells (DCs) are potent antigen-presenting cells currently being 
      investigated as a tool for antitumor vaccination strategies. As an alternative to 
      loading DCs with tumor antigen preparations, hybrid cells generated by fusing 
      tumor cells with DCs have successfully been evaluated in preclinical cancer 
      models. Hybrid cells express a large repertoire of tumor-associated antigens, 
      high levels of major histocompatibility complex class I and II molecules, and 
      adhesion/co-stimulatory molecules. Therefore, these cells possess properties of 
      both parental cell types that are necessary for the induction of primary helper 
      and cytotoxic T-cell responses. The results of early clinical trials suggest that 
      hybrid cell vaccination is a safe and well-tolerated procedure capable of 
      inducing T-cell responses. However, the few objective clinical responses observed 
      indicate that further optimizations are required.
FAU - Haenssle, Holger A
AU  - Haenssle HA
AD  - Georg-August University of Goettingen, Department of Dermatology, Von-Siebold-Str 
      3, D-37075 Goettingen, Germany. h.haenssle@med.uni-goettingen.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/biosynthesis/immunology/*therapeutic use
MH  - Cancer Vaccines/*therapeutic use
MH  - Cell Fusion
MH  - Dendritic Cells/immunology
MH  - Disease Models, Animal
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Hybrid Cells/*immunology/metabolism
MH  - Neoplasms, Experimental/immunology/therapy
MH  - T-Lymphocyte Subsets/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - T-Lymphocytes, Helper-Inducer/*immunology
MH  - Tumor Cells, Cultured/immunology
RF  - 66
EDAT- 2005/12/24 09:00
MHDA- 2006/06/20 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/06/20 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2005 Dec;6(12):1240-5.